Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.DuoCort Pharma's Plenadren (hydrocortisone, modified release tablet) has received European Marketing Authorisation (EMA) by the European Commission (EC), to treat adrenal insufficiency in adults.
Subscribe to our email newsletter
Plenadren, an oral once daily tablet, is a dual release hydrocortisone replacement therapy.
The move follows the satisfactory opinion adopted by the Committee for Medicinal Products for Human Use (CHMP).
DuoCort Pharma chief medical officer Gudmundur Johannsson said Plenadren can be a new cortisol replacement therapy for patients suffering from adrenal insufficiency.
Currently, Plenadren is approved in all European Union (EU) countries, Iceland, Norway and Lichtenstein.